DailyIQ
Last updatedUpdating…

ZTS·Zoetis Inc.

$75.32
+1.02 (+1.37%)
After Hours
High
$75.90
Open
$74.54
Market Cap
30.89B
52W High
$148.30
Low
$74.25
P. Close
$75.32
P/E
11.81
52W Low
$68.77
Fwd P/E
11.48
DailyIQ Est.
$98.18
Inst. Ownership
41.0%
Short Interest
4.43%
Days to Cover
4.1
Div. Yield
2.78%
Next Ex-Div
~Oct 18
Div. Growth
12+ yrs
NewEarnings release, scored · filed Aug 6, 2026Guidance lowered · tone -5.3 vs prior release · 70 lines scoredSee the breakdown
Technical Score (1D)
5
BEARISH
News Sentiment
50
MIXED
On Oct 14, Zoetis announced the addition of Iris Knobloch to its board of directors and reaffirmed its fourth‑quarter dividend at $0.53 per share, a move framed as a governance and income boost amid modest share price gains. The company noted that long‑term shareholder returns have weakened, with a 47% decline over the past year and a 62% drop over five years, indicating that the announcement does not materially alter the valuation outlook. On Oct 13, the company also reported that its Q2 results contributed to a 6.6% revenue beat across tracked branded pharmaceutical stocks, reflecting broader sector tailwinds such as precision medicine, AI adoption, and demand for chronic disease treatments. That same day, the appointment of Iris Knobloch was highlighted as a strategic effort to strengthen leadership and oversight, bringing extensive animal health expertise to the board. No immediate financial impact or guidance changes were reported, leaving the overall outlook largely unchanged.
LOW TARGET
$80 +6.3%
3 analysts
MEAN TARGET
$95 +26.0%
10 analysts
HIGH TARGET
$155 +105.9%
13 analysts
PRICE RANGE
$80.00 - $155.00
SB / B / H / S / SS
4/8/12/1/1
DAILYIQ EST.
$98.18 (+30.4%)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYQ
Country
United States
Website
Symbol
ZTS
Description
Zoetis Inc. is a global leader in animal health, focused on developing and delivering a comprehensive portfolio of medicines, vaccines, diagnostic products, and services for both livestock and companion animals. The company's core value proposition lies in its broad product offerings, spanning parasiticides, vaccines, and diagnostics, catering to a diverse range of species including cattle, swine, poultry, dogs, and cats. Zoetis commercializes its products through various channels, targeting veterinarians, livestock producers, and pet owners. This expansive reach, combined with its commitment to innovation, including a collaboration for novel antibiotic development, positions Zoetis as a key player in the growing animal health market. Founded in 1950, the company is headquartered in Parsippany, New Jersey.
Bought (1Y)
0 shares
$0
Sold (1Y)
274 shares
$19K
Ferran Astorga JeannetteExecutive Vice President
Award/Grant52.983 shares2026-10-09
Driscoll RimmaExecutive Vice President
Award/Grant277.772 shares2026-10-09
Lagano RoxanneExecutive Vice President
Award/Grant367.788 shares2026-10-09
Nayak Abhay UExecutive Vice President
Award/Grant321.495 shares2026-10-09
Sarbaugh KeithExecutive Vice President
Award/Grant303.49 shares2026-10-09
73/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
28.2%
Revenue CAGR
5.9%
Current Ratio
3.03x
Debt / Equity
2.71x
Return on Equity
80.2%
Earnings Summary
Zoetis Inc. is a global leader in animal health, offering a broad portfolio of medicines, vaccines, diagnostics, and services for livestock and companion animals, operating within the specialty drug manufacturing sector. The company’s extensive product range and global sales network position it as a key player in the growing animal health market. In the most recent quarters, Zoetis reported EPS of $1.48 in Q4 2025 and $1.53 in Q1 2026, both slightly below analyst expectations of $1.616 and $1.615, respectively, while revenue rose to $2.387 billion in Q1 2026 from $2.387 billion in Q4 2025, reflecting a modest 3.66% decline versus the prior year’s $2.387 billion estimate. The company’s EPS trend shows a slight acceleration from $1.4 in Q4 2024 to $1.76 in Q2 2025, followed by a dip to $1.7 in Q3 2025 and a modest decline to $1.48 in Q4 2025, indicating volatility but generally positive momentum. Historically, Zoetis has maintained a YoY revenue growth trajectory, with revenue increasing from $2.317 billion in Q4 2024 to $2.467 billion in Q2 2026, while EPS has fluctuated around analyst estimates, often beating in Q2 2025 but missing in Q4 2025 and Q1 2026. This pattern suggests that revenue growth can persist even when EPS misses expectations, likely due to margin pressures or product mix shifts. Recent news highlights concerns about the durability of Zoetis’s competitive moat as patents expire, with analysts projecting a 10.59% decline in EPS to $1.52 and a 3.66% drop in revenue to $2.31 billion for the quarter ending November 5, 2026, potentially impacting investor sentiment.

EPS

EstBeatMiss
$1.42$1.55$1.68$1.81$1.93Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.51 - -
Q2'26$1.87$1.87-0.2%
Q1'26$1.62$1.53-5.3%
Q4'25$1.62$1.48-8.4%
Q3'25$1.62$1.70+4.8%
Q2'25$1.61$1.76+9.2%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.5B$2.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.3B - -
Q2'26$2.5B$2.5B-2.3%
Q1'26$2.3B$2.3B-2.8%
Q4'25$2.3B$2.4B+3.1%
Q3'25 - $2.4B -
Q2'25 - $2.5B -

Market Data

ZTS Stock Snapshot

BEARISH5/100
$75.22−$0.10 (0.1%)
Market cap
30.89B
P/E ratio
11.8
Day range
$74.25 – $75.90
News sentiment
50/100 · Neutral
Analyst target
$94.86 (+26.1%)
Consensus
Hold · 26 analysts
52-week range+9.4% off low · -49.3% from high
$68.77$148.30
Price $75.22 DailyIQ Est. $98.18

Price action on ZTS is defensive - rallies are being sold rather than extended. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Behaviour On Record

What ZTS's own history says about today's numbers

Realized volatility (21d)
21.0% 42nd pct
Below its peak
-69.9%
vs 200-day average
-23.2%
Up days (1y)
46%

Zoetis Inc. is currently running 21.0% annualised volatility over the last 21 sessions. Measured against ZTS's own 13 years of daily returns rather than a market-wide average, that is the 42nd percentile — close to its own typical level, against a typical reading of 22.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ZTS is trading -69.9% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -19.6%, and the deepest was -43.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -23.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 4th percentile — a narrower gap than it typically runs. Over the past year ZTS closed higher on 46% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 14 years of records, ZTS finished the month higher 5 of 14 times, with a median return of -1.5% and an average of -0.8%. Its strongest month historically has been July at +3.7% on average, its weakest March at -2.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ZTS has opened more than 2% away from the prior close in 79 of 3,268 sessions (2.4% of the time), with the largest gaps running +7.7% and -6.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ZTS moved an average of 4.3% in the session after earnings, closing higher 1 of those 3 times, with a median move of -5.6% and a largest of -6.2%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ZTS's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ZTS's sector?

Zoetis Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for ZTS?

CallsPuts

For Zoetis Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.90), with at-the-money implied volatility around 42.3%. The options market is pricing roughly a ±3.0% move by that expiry — a range of about $71.44–$75.93.

Put/call ratio (2026-10-16)
0.90
ATM implied volatility
42.3%
Total open interest
21,736
Expected move by 2026-10-16
±3.0% ($71.44–$75.93)

Analyst Rating Changes

Are analysts turning bullish or bearish on ZTS?

TD Cowen most recently reiterated its rating on Zoetis Inc. to Buy on Aug 25, 2026 with a price target of $94 (from $104). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
TD Cowen — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Aug 25, 2026TD CowenMaintainedBuy$104 → $94
Aug 20, 2026StifelMaintainedHold$85 → $80
Aug 11, 2026CitigroupMaintainedBuy$112 → $96
Aug 11, 2026BNP ParibasMaintainedOutperform$146 → $110
Aug 10, 2026Piper SandlerMaintainedNeutral$90 → $80
Aug 7, 2026UBSMaintainedNeutral$85 → $80
Aug 7, 2026JP MorganMaintainedOverweight$130 → $115
Aug 6, 2026William BlairDowngradeOutperform → Market Perform-
Jul 27, 2026UBSMaintainedNeutral$99 → $85
Jul 22, 2026Morgan StanleyMaintainedOverweight$115 → $99
Jul 6, 2026HSBCMaintainedBuy$140 → $95
Jul 1, 2026BarclaysMaintainedEqual-Weight$136 → $85

Earnings Release, Scored

What did Zoetis Inc.'s latest earnings release say?

Filed Aug 6, 2026 · SEC Form 8-K, Exhibit 99

Guidance lowered
Tone59.5/ 100-5.3 vs prior release
Hedging words0.07per 100 words-0.09 vs prior release
Tone, last 2 releasesScale 50–70

Most important lines

  1. 1

    Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)%

    Guidance lowered
  2. 2

    Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)%

    Guidance loweredNew this quarter
  3. 3

    The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational 1 basis.

    Negative tone

Peers & ETF holders

ZTS peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Zoetis announced the addition of Iris Knobloch to its board and confirmed a fourth‑quarter dividend of $0.53 per share. The move was framed as a governance and income boost amid a period of modest share price gains. However, the company’s long‑term shareholder returns remain weak, with a 47% decline over the past year and a 62% drop over five years. The announcement signals stability but does not materially alter the company’s valuation outlook.
What did this article say?
The article reviews Zoetis’ Q2 performance within the broader branded pharmaceuticals sector. It notes that the company’s results were part of a group that beat revenue estimates by 6.6%. The piece outlines industry tailwinds such as precision medicine and AI adoption, while also highlighting headwinds like regulatory scrutiny, pricing pressure, and upcoming patent cliffs. No specific guidance changes or material events for Zoetis were reported, leaving the outlook largely unchanged.
What did this article say?
Zoetis announced on October 13 that Iris Knobloch would join its Board of Directors. Knobloch brings extensive experience in animal health and corporate governance from her previous roles. The appointment is viewed as a strategic move to strengthen the company’s leadership and oversight. No immediate financial impact was reported, but the addition may enhance stakeholder confidence.
What did this article say?
Zoetis’ share price has been under pressure for several years, prompting investors to reassess whether the current valuation aligns with earnings power. Recent business updates highlighted competitive pressure in dermatology and parasiticides, while new data on Simparica Trio offered some product‑level optimism. The mixed nature of the updates suggests a cautious outlook, with the market uncertain about the durability of future profits.
What did this article say?
Zoetis (ZTS) closed up 2.37% at $74.81 on October 9, outperforming the S&P 500’s 0.6% gain. The animal‑health company’s stock outpaced the broader market despite a modest 0.3% monthly gain. Analysts noted that the upcoming earnings report on November 5 is expected to show a 10.59% decline in EPS to $1.52 and a 3.66% drop in quarterly revenue to $2.31 billion. Forecasts for the full year predict earnings of $6.20 per share and revenue of $9.24 billion, both slightly lower than the prior year. Investors are watching the earnings announcement closely as it may influence the stock’s future trajectory.
What did this article say?
The Motley Fool article highlighted that Zoetis (ZTS) has seen a 52% decline from its 52‑week high, citing stalled progress on next‑generation osteoarthritis medicines for dogs and cats. The writer noted that the company’s growth narrative has been disrupted by these delays, leading to a negative outlook for the stock. The piece also mentioned continued declines in U.S. veterinary sales, further weighing on the company’s prospects. Overall, the article conveyed a cautious view of Zoetis’s near‑term performance.
What did this article say?
Zoetis maintained its status as a dividend-paying stock with a robust 20.56% dividend growth and a low payout ratio, underscoring its profitability. However, the company’s earnings growth has slowed, presenting a potential risk to future dividend sustainability. The combination of solid dividend performance and earnings headwinds suggests a modest downside risk for investors relying on income. Overall, the company’s financial health remains solid, but the earnings slowdown tempers enthusiasm.
What did this article say?
On October 8, 2026, Zoetis’ Board declared a $0.53 per share dividend for the fourth quarter of 2026, payable on December 1, 2026 to record holders as of October 30, 2026. The dividend reflects the company’s ongoing commitment to returning value to shareholders while maintaining its focus on animal health innovation.
What did this article say?
Zoetis reported peer‑reviewed data indicating its Simparica Trio product offered stronger protection against a resistant heartworm strain than the competitor NexGard Plus. The study highlights the company’s focus on precision parasite control amid rising resistance concerns. The result supports Zoetis’s broader strategy to deliver advanced veterinary solutions and may reinforce its market position in the pet health segment.
What did this article say?
Zoetis released the transcript of its second‑quarter 2026 earnings call on October 6. The company discussed its financial performance for the period, including revenue, earnings per share, and guidance. No significant deviations from expectations or material events were highlighted in the transcript. The disclosure provides investors with detailed commentary from management but does not indicate any major upside or downside catalysts.

Technical Analysis

Real-time indicators across multiple timeframes

5
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $14.80B combined position · 12 adding, 13 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy47,780,97411.49%$6.01B2026-01-29
BlackRock, Inc.▲ Buy39,430,1819.48%$2.83B2026-08-07
Geode Capital Management, LLC▲ Buy13,289,6223.19%$951.79M2026-08-12
Wellington Management Group LLP▼ Sell9,423,8952.27%$677.20M2026-08-14
Morgan Stanley▼ Sell8,878,8492.13%$638.03M2026-08-13
Janus Henderson Group plc▼ Sell3,701,7470.89%$437.57M2026-05-18
Northern Trust Corp▼ Sell5,542,2341.33%$398.26M2026-08-13
Invesco Ltd.▲ Buy5,523,0181.33%$396.88M2026-08-14
Norges Bank▼ Sell4,689,8471.13%$337.01M2026-08-12
Bank of America Corp▼ Sell3,924,9260.94%$282.05M2026-08-14
Goldman Sachs Group Inc▼ Sell3,199,7990.77%$229.94M2026-08-14
Citadel Advisors LLC▲ Buy3,188,2630.77%$229.11M2026-09-02
JPMorgan Chase & Co▼ Sell2,624,8250.63%$192.27M2026-08-12
Ruane, Cunniff & Goldfarb L.P.▼ Sell2,353,3000.57%$169.11M2026-08-14
Millennium Management LLC▲ Buy1,813,7590.44%$130.34M2026-08-14
Wells Fargo & Company▼ Sell1,809,2780.43%$130.01M2026-08-14
Man Group plc▲ Buy1,805,0030.43%$129.71M2026-08-14
Susquehanna International Group, LLP▲ Buy1,504,3580.36%$108.10M2026-08-14
Renaissance Technologies LLC▲ Buy1,403,3000.34%$100.84M2026-08-13
Citigroup Inc▲ Buy1,265,2100.30%$90.92M2026-08-03
AllianceBernstein L.P.▼ Sell698,4520.17%$82.56M2026-08-14
AQR Capital Management LLC▲ Buy1,070,9290.26%$76.96M2026-08-14
Capital Research Global Investors▼ Sell980,8110.24%$70.48M2026-08-12
Neuberger Berman Group LLC▼ Sell634,6610.15%$45.61M2026-08-13
Squarepoint Ops LLC▲ Buy633,3700.15%$45.51M2026-08-14
Q2 2026 flow:14.86M sh bought ($1.07B)16.69M sh sold ($1.34B)net -1.83M sh (−$269.07M)
Congressional Trading Activity
25 disclosed trades · ~$322.5K est. traded value · 12 buys, 13 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-09-182026-10-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-07-172026-09-04
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-162026-07-02
Byron DonaldsHouseFL19▲ Buy$1K - $15K2026-06-092026-07-15
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-04-142026-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-03-132026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-02-102026-03-09
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-192026-01-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Rick LarsenHouseWA02▼ Sell$1K - $15K2025-10-062025-10-16
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-072025-05-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-052025-04-11
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-03-032025-04-14
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-01-152025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2024-12-112025-08-13
Shelley Moore CapitoSenateWV▲ Buy$15K - $50K2024-02-272024-03-15